炎症性肠病生物制剂应用进展

Progress in the Application of Biological Agents in Inflammatory Bowel Disease

炎症性肠病(IBD)传统用药包括氨基水杨酸类、激素、免疫抑制剂,而对于一些难治性炎症性肠病,生物制剂有着重要应用前景。IBD的生物制剂主要包括:肿瘤坏死因子(TNF)-α拮抗剂如英夫利昔单抗(Infliximab)、阿达木单抗(Adalimumab)、赛妥珠单抗(Certolizumab)、戈利木单抗(Golimumab);整合素拮抗剂如那他珠单抗(Natalizumab)、维多珠单抗(Vedolizumab);酪氨酸激酶(JAK)拮抗剂托法替尼(Tofacitinib);白细胞介素(IL)抗体优斯它单抗(Ustekinumab)。本文就上述生物制剂疗效、副作用等做简要介绍。

Inflammatory bowel disease（IBD） in traditional medicine include aminosalicylic acid, hormone and immunosuppressive agents, For some refractory inflammatory bowel disease, biological agents have important application prospects. Biological agents IBD mainly include： tumor necrosis factor（TNF） alpha antagonists such as infliximab, adalimumab（Infliximab）（Adalimumab）, race trastuzumab（Certolizumab）, golimumab（Golimumab）, integrin antagonists such as natalizumab（Natalizumab）, Weiduozhu monoclonal antibody（Vedolizumab）, tyrosine kinase（JAK） antagonist（Tofacitinib）, interleukin（IL） antibody, monoclonal antibody（Ustekinumab）. This paper briefly introduces the therapeutic effect and side effects of the biological agents.